Skip to main navigation
Go to Cumberland Pharmaceuticals, Inc. homepage
  • About Us
    • Profile & Mission
    • Our Strategy
    • Board of Directors
    • Management Team
    • Company History
  • Our Products
    • Commercial Products
    • Pipeline Products
    • International Partners
  • Investor Relations
    • Overview
    • Corporate Update
    • Corporate Governance
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Historic Price Lookup
      • Ownership Profile
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
      • Key Ratios
    • Earnings Calls & Presentations
    • Investor FAQs
    • Press Releases
    • Contact Investor Relations
  • News
  • Cumberland Emerging Technologies
  • Blog
  • About Us
    • Profile & Mission
    • Our Strategy
    • Board of Directors
    • Management Team
    • Company History
  • Our Products
    • Commercial Products
    • Pipeline Products
    • International Partners
  • Investor Relations
    • Overview
    • Corporate Update
    • Corporate Governance
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Historic Price Lookup
      • Ownership Profile
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
      • Key Ratios
    • Earnings Calls & Presentations
    • Investor FAQs
    • Press Releases
    • Contact Investor Relations
  • News
  • Cumberland Emerging Technologies
  • Blog
Contact
Contact

Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York

May 15, 2013
Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York 11.2 KB

NASHVILLE, Tenn., May 15, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the UBS Global Healthcare Conference at the Sheraton New York hotel on Monday, May 20, 2013, at 9:30 a.m. Eastern Time.

The presentation will be simultaneously webcast and can be accessed through the Investor Relations section of Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.

Shortly following the live webcast a replay will also be available on the Company's website.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote® for the treatment of acetaminophen poisoning, Caldolor®, the first injectable treatment for pain and fever approved in the United States, and Kristalose®, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information, please visit the Company website at www.cumberlandpharma.com.

 

SOURCE Cumberland Pharmaceuticals Inc.

News Provided by Acquire Media

© 2026 Cumberland Pharmaceuticals, Inc. All Rights Reserved.

Privacy Policy
Accessibility Statement
Terms of Use